Design Therapeutics, Inc. (DSGN)
$14.09
Rating:
Recommendation:
-
| Symbol | DSGN |
|---|---|
| Price | $14.09 |
| Beta | 0.000 |
| Volume Avg. | 0.20M |
| Market Cap | 785.974M |
| Shares () | - |
| 52 Week Range | 9.61-22.2 |
| 1y Target Est | - |
| DCF Unlevered | DSGN DCF -> | |
|---|---|---|
| DCF Levered | DSGN LDCF -> | |
| ROE | -11.20% | Sell |
| ROA | -11.43% | Sell |
| Operating Margin | - | |
| Debt / Equity | 2.29% | Neutral |
| P/E | - | |
| P/B | 2.11 | Strong Buy |
Latest DSGN news
About
Download (Excel)Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.